Search

Search Constraints

You searched for: Author/Creator Bernstein, David

Search Results

1. 1333Therapeutic HSV-2 vaccine (GEN003) results in durable reduction in genital lesions at 1 year. (December 2014)

2. 821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results. (December 2014)

3. 99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b‐Infected Patients Treated With Label‐Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin: 2016. (October 2015)

4. 997Saliva vs Urine PCR: The Ideal Sample for congenital CMV Screening and Diagnosis. (December 2014)

6. Agency notification and retrospective self-reports of childhood maltreatment in a 30-Year cohort: Estimating population prevalence from different data sources. (November 2020)

7. All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study. Issue 4 (10th March 2015)

9. An external dosimetry audit programme to credential static and rotational IMRT delivery for clinical trials quality assurance. (March 2017)

10. Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo. (4th October 2017)